A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus

NCT00203151 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

340

Enrollment

INDUSTRY

Sponsor class

Stopped TV-4710/201 did not meet its primary endpoints in patients with SLE

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: edratide

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.